Sustained impact of nosocomial-acquired spontaneous bacterial peritonitis in different stages of decompensated liver cirrhosis.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
06
05
2019
accepted:
20
07
2019
entrez:
3
8
2019
pubmed:
3
8
2019
medline:
7
3
2020
Statut:
epublish
Résumé
Bacterial infections, in particular a spontaneous bacterial peritonitis (SBP), are a major threat in patients with liver cirrhosis. Recently, it has been shown that the impact on mortality might be underestimated by established risk-scores. Onset of infection was suggested to define a distinct stage of cirrhosis. However, it remains unclear whether all stages of decompensated cirrhosis are equally affected. Moreover, if there is such a distinct stage, it must be determined whether it is reversible after the infection has resolved. In this study we aimed to further analyze the impact of a current as well as a resolved SBP in different stages of decompensated liver cirrhosis. A number of 579 patients with liver cirrhosis and ascites were included. MELD-score was used to determine the stage of liver disease. Low (<15), intermediate (15-25) and high (>25) MELD-groups were compared. Patients were followed up for 90 days. Primary endpoint was overall mortality. Statistical analyses were performed using the log-rank test, Cox regression and competing risk analysis. Mortality was significantly higher in patients with nosocomial-acquired SBP (nSBP) compared to patients without SBP (p<0.001;HR = 2.05). However, the most prominent difference in mortality was documented in the intermediate MELD-group (nSBP: p = 0.02;HR = 2.10). Importantly, mortality in nSBP patients remained increased even after the initial nSBP episode had resolved (p<0.01;HR = 1.90). Again, this was only significant in those with intermediate MELD-scores (p = 0.02;HR = 2.28). While a current as well as a resolved nSBP were significantly linked to a higher mortality, neither of them did increase the likelihood for liver transplantation. Development of nSBP is independently associated with increased mortality supporting the concept of a distinct status of cirrhosis. Importantly, the prognosis remains unfavorable even after resolution of nSBP. This could be particularly relevant for patients with intermediate MELD-scores, who have limited chances for a donor liver.
Sections du résumé
BACKGROUND & AIMS
Bacterial infections, in particular a spontaneous bacterial peritonitis (SBP), are a major threat in patients with liver cirrhosis. Recently, it has been shown that the impact on mortality might be underestimated by established risk-scores. Onset of infection was suggested to define a distinct stage of cirrhosis. However, it remains unclear whether all stages of decompensated cirrhosis are equally affected. Moreover, if there is such a distinct stage, it must be determined whether it is reversible after the infection has resolved. In this study we aimed to further analyze the impact of a current as well as a resolved SBP in different stages of decompensated liver cirrhosis.
METHODS
A number of 579 patients with liver cirrhosis and ascites were included. MELD-score was used to determine the stage of liver disease. Low (<15), intermediate (15-25) and high (>25) MELD-groups were compared. Patients were followed up for 90 days. Primary endpoint was overall mortality. Statistical analyses were performed using the log-rank test, Cox regression and competing risk analysis.
RESULTS
Mortality was significantly higher in patients with nosocomial-acquired SBP (nSBP) compared to patients without SBP (p<0.001;HR = 2.05). However, the most prominent difference in mortality was documented in the intermediate MELD-group (nSBP: p = 0.02;HR = 2.10). Importantly, mortality in nSBP patients remained increased even after the initial nSBP episode had resolved (p<0.01;HR = 1.90). Again, this was only significant in those with intermediate MELD-scores (p = 0.02;HR = 2.28). While a current as well as a resolved nSBP were significantly linked to a higher mortality, neither of them did increase the likelihood for liver transplantation.
CONCLUSIONS
Development of nSBP is independently associated with increased mortality supporting the concept of a distinct status of cirrhosis. Importantly, the prognosis remains unfavorable even after resolution of nSBP. This could be particularly relevant for patients with intermediate MELD-scores, who have limited chances for a donor liver.
Identifiants
pubmed: 31374111
doi: 10.1371/journal.pone.0220666
pii: PONE-D-19-12752
pmc: PMC6677299
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0220666Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Hepatology. 2001 Feb;33(2):464-70
pubmed: 11172350
Hepatology. 2002 Jan;35(1):140-8
pubmed: 11786970
J Gastroenterol Hepatol. 2003 Aug;18(8):927-33
pubmed: 12859722
Gastroenterology. 2006 Oct;131(4):1049-56; quiz 1285
pubmed: 17030175
Hepatology. 2007 Mar;45(3):797-805
pubmed: 17326206
Bone Marrow Transplant. 2007 Aug;40(4):381-7
pubmed: 17563735
Clin Infect Dis. 2009 May 1;48(9):1230-6
pubmed: 19302016
Gastroenterology. 2010 Oct;139(4):1246-56, 1256.e1-5
pubmed: 20558165
Aliment Pharmacol Ther. 2011 Jan;33(2):275-84
pubmed: 21083594
Z Gastroenterol. 2011 Jun;49(6):780-7
pubmed: 21638243
Hepatology. 1990 Oct;12(4 Pt 1):716-24
pubmed: 2210673
Hepatology. 2012 May;55(5):1551-61
pubmed: 22183941
Gastroenterology. 2013 Jun;144(7):1426-37, 1437.e1-9
pubmed: 23474284
J Hepatol. 2014 Jun;60(6):1310-24
pubmed: 24530646
J Hepatol. 2014 Oct;61(4):725-6
pubmed: 24996045
J Hepatol. 2014 Dec;61(6):1385-96
pubmed: 25135860
Hepatology. 2015 Jul;62(1):243-52
pubmed: 25877702
Hepatology. 2016 Apr;63(4):1299-309
pubmed: 26084406
Hepatol Int. 2013 Mar;7(1):72-9
pubmed: 26201623
Hepatology. 2016 Jun;63(6):2019-31
pubmed: 26528864
World J Gastroenterol. 2015 Nov 7;21(41):11493-501
pubmed: 26556982
Semin Liver Dis. 2016 May;36(2):109-16
pubmed: 27172351
Transplantation. 2017 Jul;101(7):1542-1550
pubmed: 28060242
Am J Gastroenterol. 2017 Apr;112(4):588-596
pubmed: 28220780
Am J Infect Control. 1988 Jun;16(3):128-40
pubmed: 2841893
Ann Hepatol. 2017 Aug 1;16(4):584-590
pubmed: 28611262
Gut. 2018 Oct;67(10):1870-1880
pubmed: 28847867
Liver Int. 2018 Apr;38(4):645-653
pubmed: 28853199
J Hepatol. 2018 Mar;68(3):563-576
pubmed: 29111320
Liver Int. 2018 Sep;38(9):1602-1613
pubmed: 29675988
J Hepatol. 2018 Nov;69(5):1207
pubmed: 30172388
Clin Transl Gastroenterol. 2018 Sep 24;9(9):189
pubmed: 30250034